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No area of healthcare is immune to the impact of COVID-19. The pandemic will affect sexual and 
reproductive health (SRH) worldwide in positive and negative ways. Home-isolation and fears of 
contracting the virus appear to have led to decreased uptake of SRH services, increased reports of 
intimate partner violence and in some settings reduced access to contraception and safe abortion 
care.1 2 Vulnerable populations are disproportionately affected, including young people, Indigenous 
people as well as refugees and asylum-seekers whose safety and care is deprioritised.3 Predictions 
have been made about higher rates of unintended pregnancy, unsafe abortion, short interpregnancy 
intervals, and untreated sexually transmitted infections. 4 
The pandemic has also led to rapid implementation of innovations and legal and regulatory changes 
that have transformed and improved care for some people. In many countries contraception and 
abortion care have been classified as essential services, and recognition for the pivotal role of nurses 
and midwives has grown. New policies, practices and even enactment of laws have removed barriers 
to care which could otherwise take years of bureaucracy to overturn. This editorial draws on the 
expertise of a range of international clinicians and researchers to examine these changes to policy 
and practice, many of which may have lasting benefits for women. 
Contraception care  
 
 
Many countries have recognised continuity of contraception provision, particularly long acting 
reversible contraception (LARC), as essential. There has been a significant shift to telemedicine, for 
instance in US, Canada, UK, France, Australia, Scandinavia, China, South Africa and Nepal.5, 6 7 Some 
countries have been able to maintain LARC access through brief procedural visits with appropriate 
personal protective equipment (PPE) following a virtual consultation. In some parts of the world the 
rapid development of clinical guidance to permit the off-label extended use of LARC has served to 
support those unable to attend scheduled removal and reinsertion visits. 5, 7 
Innovations include ‘click and collect’ policies allowing contraceptive prescriptions to be sent directly 
to pharmacies after a ‘telephone/ video visit’ or a supply of pills to be sent directly to a woman’s 
home. In France women have been enabled to obtain extra supplies of their combined hormonal 
contraceptive pills without renewed prescriptions. The UK Faculty of Sexual and Reproductive 
Healthcare and the Society of Obstetricians and Gynaecologists of Canada have supported use of the 
progestogen-only-pill during the pandemic, as it can be supplied for up to a year to new users 
without a baseline blood pressure, and both organisations support remote prescribing of an 
additional year’s  supply of the combined pill.5, 7 California has rapidly approved drive-through 
contraceptive injection services and direct pharmacy provision of self-injectables, a change which 
may otherwise have taken years. Welcome changes have also occurred in some humanitarian 
settings, including amongst Syrian refugees in Lebanon who can now access free contraception 
through local clinics.  
Abortion care  
In many countries abortion has been designated an essential service in recognition that access 
cannot be delayed or postponed without impacting physical and psychological well-being, but others 
have used it as an excuse to constrain services. In the US, for instance, some states have attempted 
to restrict or prohibit abortion services, although injunctions against these policies have mostly been 





The need to keep women out of hospital, and to protect both women and clinicians from exposure 
to COVID-19, has resulted in a shift from surgical to medical abortion. Simultaneously, access to 
medical abortion has been enhanced by new policies, practices and even enactment of laws. While 
the benefits of self-managed medical abortion have been recognised for years, rapid adoption has 
occurred in some jurisdictions where it was previously unattainable. Abortion regulations in England, 
Scotland and Wales now allow home administration of both mifepristone and misoprostol supported 
by telemedicine, while regulatory changes have extended the upper gestational limit from 9 to 10-
weeks in Finland, to 12-weeks in Scotland9 and from 7 to 9 weeks in France. New regulations in 
Northern Ireland do not permit mifepristone at home, but consultations can now be undertaken 
remotely followed by a short in-person visit.  
Protocols for ‘no-test/no touch medical abortion’ have been published,10 and countries such as 
Canada,5 where abortion is fully decriminalized and has been regulated as a publicly funded health 
service for over 30 years, have quickly transitioned to a virtual health model. In Britain, policies 
include a service model where an ultrasound scan is only  undertaken if a reliable Last Menstrual 
Period (LMP) cannot be provided or the history is concerning for an ectopic pregnancy.9 Similarly, 
while the 2019 NICE guidelines obviated the need for anti-D for Rhesus negative women undertaking 
medical abortion below 10-weeks, it had not been taken up in Australia or Canada until the start of 
the pandemic, and Scotland rapidly approved an extension to 12-weeks. Adoption of low sensitivity 
urine pregnancy tests that detect hCG levels over 1000 IU/L to confirm completion of a home 
medical abortion has also supported the shift to person-centred  care. 
Ensuring evidence-based sustainable change  
Despite strong evidence of the safety and effectiveness of many of these practice changes, 
regulatory and legislative restrictions have impeded their implementation in many parts of the 
 
 
world.  During the pandemic, the most progressive jurisdictions have consolidated existing practices 
to ensure access to SRH services, while others have moved swiftly to lift unnecessary regulations. 
However, many still lag behind or, as in the case of Poland and Hungary and some US states, are 
taking advantage of COVID-19 to further restrict access.  
The pandemic provides a unique opportunity for coordinated research and data collection through 
newly formed networks to support sustainable change. Sharing of these learnings could potentially 
reduce inequality of access to SRH services in a range of settings  provided that quality and safety of 
care are not compromised. Despite its many benefits, telemedicine should not be blindly 
implemented as a cost-saving measure. It does not always, for instance, lend itself well to screening 
for and disclosure of intimate partner violence including reproductive coercion, as conversations 
may be overheard or intercepted. Care should also be taken to avoid the loss of a skilled surgical 
abortion workforce with the shift to medical abortion which will remove the opportunity to choose 
the method which best suits their circumstances. Consumer involvement is essential to protect 
personal preferences and choices for telemedicine or face-to-face consultation, for methods of 
contraception, and for medical versus surgical abortion.  
The current global pandemic presents an unparalleled opportunity to advance sustainable policy and 
services ensuring person-centred contraception and abortion care. Sexual and reproductive health 
and rights must encompass equitable access to quality care which upholds the principles of 
autonomy, confidentiality and dignity. We need to make these changes endure. 
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